117 related articles for article (PubMed ID: 38679017)
1. The Hammersmith Score Optimises Patient Selection and Predicts for Overall Survival in Early-Phase Cancer Trial Participants Independent of Tumour Burden.
Korolewicz JA; Scheiner B; Fulgenzi CAM; D'Alessio A; Cortellini A; Pascual C; Mehan A; Partridge S; Gujral DM; Mohammed W; Mohammed O; Grzesiak A; Booker L; Cleator S; Pokrovska T; Saleem W; Rackie J; Needham Y; Krell J; McNeish I; Tookman L; Park WE; Asif M; Evans JS; Pinato DJ
Chemotherapy; 2024 Apr; ():1-7. PubMed ID: 38679017
[TBL] [Abstract][Full Text] [Related]
2. Developing an objective marker to optimize patient selection and predict survival benefit in early-phase cancer trials.
Stavraka C; Pinato DJ; Turnbull SJ; Flynn MJ; Forster MD; O'Cathail SM; Babar S; Seckl MJ; Kristeleit RS; Blagden SP
Cancer; 2014 Jan; 120(2):262-70. PubMed ID: 24399418
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Prognostic Scores in Early Phase Clinical Trials: A 10-year Single Centre Australian Experience.
Childs S; Nindra U; Yoon R; Haider S; Hong M; Roohullah A; Cooper A; Wilkinson K; Chua W; Pal A
Anticancer Res; 2024 May; 44(5):2095-2102. PubMed ID: 38677731
[TBL] [Abstract][Full Text] [Related]
4. Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score).
Bigot F; Castanon E; Baldini C; Hollebecque A; Carmona A; Postel-Vinay S; Angevin E; Armand JP; Ribrag V; Aspeslagh S; Varga A; Bahleda R; Menis J; Gazzah A; Michot JM; Marabelle A; Soria JC; Massard C
Eur J Cancer; 2017 Oct; 84():212-218. PubMed ID: 28826074
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of preoperative high-sensitivity modified Glasgow prognostic score in advanced colon cancer: a retrospective observational study.
Kasahara K; Enomoto M; Udo R; Tago T; Mazaki J; Ishizaki T; Yamada T; Nagakawa Y; Katsumata K; Tsuchida A
BMC Cancer; 2022 Jan; 22(1):20. PubMed ID: 34980009
[TBL] [Abstract][Full Text] [Related]
6. Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study.
Muñoz-González JI; Álvarez-Twose I; Jara-Acevedo M; Zanotti R; Perkins C; Jawhar M; Sperr WR; Shoumariyeh K; Schwaab J; Greiner G; Henriques A; Caldas C; Fernández-Giménez C; Sánchez-Muñoz L; Mayado A; Pérez-Pons A; Schmitt-Graeff A; Duyster J; Tanasi I; Olivieri F; Mora-Casterá E; Luna I; Senent L; Bañas MH; Nuñez-García A; Jurado-Chacón M; Martín-Sánchez G; Colado E; Xicoy B; Gener-Ricós G; Gotlib J; Bonadonna P; Reiter A; Valent P; García-Montero AC; Orfao A
Lancet Haematol; 2021 Mar; 8(3):e194-e204. PubMed ID: 33508247
[TBL] [Abstract][Full Text] [Related]
7. Gustave Roussy Immune Score and Royal Marsden Hospital Prognostic Score Are Biomarkers of Immune-Checkpoint Inhibitor for Non-Small Cell Lung Cancer.
Minami S; Ihara S; Ikuta S; Komuta K
World J Oncol; 2019 Apr; 10(2):90-100. PubMed ID: 31068989
[TBL] [Abstract][Full Text] [Related]
8. High-sensitivity modified Glasgow prognostic score (HS-mGPS) Is superior to the mGPS in esophageal cancer patients treated with chemoradiotherapy.
Chen P; Fang M; Wan Q; Zhang X; Song T; Wu S
Oncotarget; 2017 Nov; 8(59):99861-99870. PubMed ID: 29245945
[TBL] [Abstract][Full Text] [Related]
9. Glasgow prognostic score is a better predictor of the long-term survival in patients with gastric cancer, compared to the modified Glasgow prognostic score or high-sensitivity modified Glasgow prognostic score.
Hirahara N; Matsubara T; Kaji S; Kawabata Y; Hyakudomi R; Yamamoto T; Uchida Y; Ishitobi K; Takai K; Tajima Y
Oncotarget; 2020 Nov; 11(45):4169-4177. PubMed ID: 33227100
[TBL] [Abstract][Full Text] [Related]
10. Gustave Roussy Immune Score and Royal Marsden Hospital Prognostic Score Are Prognostic Markers for Extensive Disease of Small Cell Lung Cancer.
Minami S; Ihara S; Komuta K
World J Oncol; 2020 Jun; 11(3):98-105. PubMed ID: 32494316
[TBL] [Abstract][Full Text] [Related]
11. Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy.
Dercle L; Ammari S; Champiat S; Massard C; Ferté C; Taihi L; Seban RD; Aspeslagh S; Mahjoubi L; Kamsu-Kom N; Robert C; Marabelle A; Schlumberger M; Soria JC; Postel-Vinay S
Eur J Cancer; 2016 Sep; 65():33-42. PubMed ID: 27451022
[TBL] [Abstract][Full Text] [Related]
12. Independent Assessment of the Children's Hepatic Tumors International Collaboration Risk Stratification for Hepatoblastoma and the Association of Tumor Histological Characteristics With Prognosis.
Zhou S; Malvar J; Chi YY; Stein J; Wang L; Genyk Y; Sposto R; Mascarenhas L
JAMA Netw Open; 2022 Feb; 5(2):e2148013. PubMed ID: 35147687
[TBL] [Abstract][Full Text] [Related]
13. Gustave Roussy Immune Score Is a Prognostic Factor for Chemotherapy-Naive Pulmonary Adenocarcinoma With Wild-Type Epidermal Growth Factor Receptor.
Minami S; Ihara S; Komuta K
World J Oncol; 2019 Feb; 10(1):55-61. PubMed ID: 30834052
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Four Clinical Prognostic Scores in Patients with Advanced Gastric and Esophageal Cancer.
Ma LX; Espin-Garcia O; Bach Y; Aoyama H; Allen MJ; Wang X; Darling GE; Yeung J; Swallow CJ; Brar S; Veit-Haibach P; Kalimuthu S; Wong R; Chen EX; O'Kane GM; Jang RW; Elimova E
Oncologist; 2023 Mar; 28(3):214-219. PubMed ID: 36378560
[TBL] [Abstract][Full Text] [Related]
15. Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.
Sgroi DC; Sestak I; Cuzick J; Zhang Y; Schnabel CA; Schroeder B; Erlander MG; Dunbier A; Sidhu K; Lopez-Knowles E; Goss PE; Dowsett M
Lancet Oncol; 2013 Oct; 14(11):1067-1076. PubMed ID: 24035531
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Role of High-Sensitivity Modified Glasgow Prognostic Score for Patients With Operated Oral Cavity Cancer: A Retrospective Study.
Tsai YT; Fang KH; Hsu CM; Lai CH; Chang SW; Huang EI; Tsai MS; Chang GH; Luan CW
Front Oncol; 2022; 12():825967. PubMed ID: 35242712
[TBL] [Abstract][Full Text] [Related]
17. Serum parameters as prognostic biomarkers in a real world cancer patient population treated with anti PD-1/PD-L1 therapy.
Minichsdorfer C; Gleiss A; Aretin MB; Schmidinger M; Fuereder T
Ann Med; 2022 Dec; 54(1):1339-1349. PubMed ID: 35535695
[TBL] [Abstract][Full Text] [Related]
18. Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials.
Alhalabi O; Hahn AW; Msaouel P; Meric-Bernstam F; Wilson N; Naing A; Piha-Paul S; Janku F; Pant S; Yap TA; Hong DS; Fu S; Karp D; Beltran K; Campbell E; Le H; Campbell MT; Shah A; Tannir NM; Siefker-Radtke A; Gao J; Roszik J; Subbiah V
Clin Genitourin Cancer; 2022 Feb; 20(1):e16-e24. PubMed ID: 34362693
[TBL] [Abstract][Full Text] [Related]
19. The high-sensitivity modified Glasgow prognostic score is superior to the modified Glasgow prognostic score as a prognostic predictor for head and neck cancer.
Hanai N; Sawabe M; Kimura T; Suzuki H; Ozawa T; Hirakawa H; Fukuda Y; Hasegawa Y
Oncotarget; 2018 Dec; 9(97):37008-37016. PubMed ID: 30651931
[TBL] [Abstract][Full Text] [Related]
20. [Predictive and Prognostic significance of high-sensitivity modified Glasgow Prognostic Score (HS-mGPS) in advanced gastric cancer patients treated with neoadjuvant chemotherapy].
Cui Y; Li J; Cao YH; Liu MY; Shi ZX; Gao TH
Zhonghua Zhong Liu Za Zhi; 2017 Mar; 39(3):195-200. PubMed ID: 28316218
[No Abstract] [Full Text] [Related]
[Next] [New Search]
